ERBB2 and breast carcinoma: On the other hand, patients with breast cancer that are triple negative (ER(−) PR(−) Her-2(−)) constitute about 15–20% of the breast cancer population lack Her2 gene and the specific disease metastasis with high recurrence rate challenges the medical experts in the management of the disease drug cannot be used for treatment [7].